TY - JOUR
T1 - Hydrogen gas therapy improves survival rate and neurological deficits in subarachnoid hemorrhage rats
T2 - A pilot study
AU - Camara, Richard
AU - Matei, Nathanael
AU - Camara, Justin
AU - Enkhjargal, Budbazar
AU - Tang, Jiping
AU - Zhang, John
N1 - Publisher Copyright:
© 2019 Medical Gas Research | Published by Wolters Kluwer - Medknow.
PY - 2019/6
Y1 - 2019/6
N2 - The high morbidity, high mortality, and significant shortage of effective therapies for subarachnoid hemorrhage (SAH) have created an urgency to discover novel therapies. Human studies in Asia have established the safety of hydrogen gas in the treatment of hepatic, renal, pulmonary, and cardiac diseases. Mechanistically, hydrogen gas has been shown to affect oxidative stress, inflammation, and apoptosis. We hypothesized that hydrogen therapy would improve neurological function and increase survival rate in SAH. High dose hydrogen gas (66% at 3 L/min) was administered for 2 hours at 0.5, 8, and 18 hours after SAH. This treatment increased 72-hour survival rate and provided 24-hour neuroprotection after SAH in rats. To our knowledge, this is the first report demonstrating that high dose hydrogen gas therapy reduces mortality and improves outcome after SAH. Our results correlate well with the proposed mechanisms of hydrogen gas therapy within the literature. We outline four pathways and downstream targets of hydrogen gas potentially responsible for our results. A potentially complex network of pathways responsible for the efficacy of hydrogen gas therapy, along with a limited mechanistic understanding of these pathways, justifies further investigation to provide a basis for clinical trials and the advancement of hydrogen gas therapy in humans. This study was approved by the Institutional Animal Care and Use Committee of Loma Linda University, USA (Approval No. 8160016) in May 2016.
AB - The high morbidity, high mortality, and significant shortage of effective therapies for subarachnoid hemorrhage (SAH) have created an urgency to discover novel therapies. Human studies in Asia have established the safety of hydrogen gas in the treatment of hepatic, renal, pulmonary, and cardiac diseases. Mechanistically, hydrogen gas has been shown to affect oxidative stress, inflammation, and apoptosis. We hypothesized that hydrogen therapy would improve neurological function and increase survival rate in SAH. High dose hydrogen gas (66% at 3 L/min) was administered for 2 hours at 0.5, 8, and 18 hours after SAH. This treatment increased 72-hour survival rate and provided 24-hour neuroprotection after SAH in rats. To our knowledge, this is the first report demonstrating that high dose hydrogen gas therapy reduces mortality and improves outcome after SAH. Our results correlate well with the proposed mechanisms of hydrogen gas therapy within the literature. We outline four pathways and downstream targets of hydrogen gas potentially responsible for our results. A potentially complex network of pathways responsible for the efficacy of hydrogen gas therapy, along with a limited mechanistic understanding of these pathways, justifies further investigation to provide a basis for clinical trials and the advancement of hydrogen gas therapy in humans. This study was approved by the Institutional Animal Care and Use Committee of Loma Linda University, USA (Approval No. 8160016) in May 2016.
KW - cerebral vasospasm
KW - early brain injury
KW - free radicals
KW - high dose hydrogen
KW - hydrogen gas therapy
KW - hydrogen pathway
KW - mortality
KW - oxidative stress
KW - reactive oxygen species
KW - subarachnoid hemorrhage
KW - survival
UR - http://www.scopus.com/inward/record.url?scp=85068558184&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068558184&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/042180f6-0301-3bda-84d9-3e7fd2d36e33/
U2 - 10.4103/2045-9912.260648
DO - 10.4103/2045-9912.260648
M3 - Article
C2 - 31249255
SN - 2045-9912
VL - 9
SP - 74
EP - 79
JO - Medical Gas Research
JF - Medical Gas Research
IS - 2
ER -